Johns Hopkins physicians reported a ~95% cure rate for sickle cell disease using a bone marrow transplant protocol developed through the Johns Hopkins Kimmel Cancer Center. The approach uses reduced-intensity conditioning and haploidentical donors, targeting lower rejection risk while aiming to preserve fertility. The report also highlights improvements in rejection incidences compared with prior transplantation experiences, positioning the regimen as a potential refinement for both sickle cell disease and thalassemia treatment strategies. If the results hold across broader settings, the protocol could influence transplant-center approaches to conditioning intensity and donor matching for curative hematology, where access and risk reduction remain major hurdles.